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Despite extensive research and deliberation, the
diagnoses of schizophrenia and other psychiatric disorders
remain enigmatically difficult and the established
diagnostic criteria, even after several critical reviews, are
continually ill-defined. Indeed, the widely used ICD-10
guidelines are in fact derived from the observations reported
by Schneider in the early part of the last century.1 Recent
advances in a wide-spectrum of technologies have enabled
investigators to utilize robust, highly sensitive and specific
biomarkers for accurate diagnoses, for example, troponin
levels for the diagnosis of an acute myocardial infarction.
With the absence of any biochemical tests, psychiatric
disorders and schizophrenia in particular, are one of the few
groups of illnesses that are clinically evaluated in their
entirety. 
Current diagnosis of schizophrenia relies on
subjective tests which often result in varying interpretations
by different clinicians for the same patient. This is further
compounded by the fact that the margins used to categorize
psychiatric illnesses clinically can be blurry. For example,
hallucinations can be a part of bipolar disorder,
schizophrenia as well as psychotic depression.2 This overlap
in symptomatology has made it challenging to classify and
distinguish these diseases.
Amongst the various identified risk factors for
schizophrenia, (e.g., obstetric complications and neonatal
infections), family history remains the most consistent
finding, suggesting that genetics contributes to its etiology
in a significant way.2 Based on familial linkage analyses,
the estimated heritability for schizophrenia is approximately
80%, which is significantly higher than that of Parkinson's
disease (13% to 30%) and breast cancer (5% to 60%), both
of which have several established genetic risk factors.3
However, these studies inherently suffer from a low power
and a recent meta-analysis failed to implicate a
chromosomal region conclusively.4 Attention is now being
focused towards case-control based association studies that
investigate specific allelic variations or single nucleotide
polymorphisms (SNPs) within possible 'candidate genes'.
Whilst these studies have provided greater statistical power,
they lack consistency in the precise genetic regions and
SNPs that have been implicated when compared to other
hereditable disorders such as diabetes.3 However, a few
genes including Disrupted in Schizophrenia 1 (DISC1),
Neuregulin 1 and Dystrobrevin binding protein 1
(DTNBP1) have been implicated in multiple population
models of schizophrenia. In addition they have supportive
neurobiological data that links the functions of these genes
to the various cellular processes thought to be disrupted in
schizophrenia.5-7 There is a need to study these genes in
more diverse ethnic populations to further validate their
roles as bona fide biomarkers for schizophrenia. 
The various biochemical theories of schizophrenia
that have emerged as a result of the available therapeutic
interventions have prompted a vigorous search for putative
biochemical biomarkers. These include glycine, serine and
homocysteine that are mediators of the NMDA pathway, the
dysfunction of which is currently the most strongly
postulated theory of schizophrenia.8,9 Other chemical
biomarkers include dehydroepiandrosterone (DHEA) and
cortisol that are involved in regulating the hypothalamic
pituitary-adrenal (HPA) axis and inflammatory markers
such as selectins, tumour necrosis factor α (TNF-α) and
nuclear factor-kappa B (NF-kB). Perhaps the most
promising of these are the recently discovered neurotrophic
factors, such as brain derived neurotrophic factor (BDNF)
that involve neuronal growth and regulation.10-13
Additionally, peripheral expression of the schizophrenia
candidate gene, NRG1, has been studied in the blood of
schizophrenic patients and this may serve as a robust
biomarker for the disease.14
Whilst schizophrenia appears to be a polygenic
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disorder, it is plausible that the defects might lie beyond the
level of the genome; it is well known that dysfunctional
epigenetic mechanisms such as DNA methylation and
histone modification during early development and later in
life may contribute to its onset. Although probing such
abnormalities to identify chemically useful biomarkers may
be challenging, structural changes in schizophrenia could
serve as reliable indicators of the disease. Reduced cortical
volumes and enlarged ventricles are long-established
findings in schizophrenia with early gray matter loss,
particularly associated with first-episode psychosis.15
Though radiological findings have been relatively
consistent, they are by no means specific to schizophrenia
and hence have limited applicability as screening or
prognostic tools. Advances in functional MRI may allow
identification of permanent disease-specific changes in the
schizophrenic brain which could in turn serve as reliable
"image-based" markers for early detection of disease.
Psychiatry seems to be experiencing a fundamental
shift in its approach to dealing with the complexity of
diseases that fall within its spectrum. Recent advances in
molecular and cellular biology and imaging technology
could enable psychiatrists to diagnose cases at a much
earlier stage. However, the apathy with which policy
makers address the issue of mental health and the general
discrimination between physical and mental disorders
amongst medical practitioners is a matter of great concern.
Lack of recognition of psychiatric disorders and of their
severity is central to this problem as cost-effective treatment
modalities are already in existence. Schizophrenia in
particular, carries an enormous economic and social burden
and this is especially pertinent in the developing world
where the prevalence rates are thought to be higher than
previously expected.16 The authors feel that clinicians in
Pakistan need to continually keep themselves abreast of the
latest developments in neuropsychiatry in an effort to learn
more about the disease and its management. Research that
helps identify accurate, precise and cost-effective
biomarkers is now crucial and this will undoubtedly result
in significantly reduced morbidity and mortality by early
identification of the disease process. Failure to do so will
continue to deprive vast swathes of population within
developing countries that suffer from undetected mental
health disorders, such as, schizophrenia from appropriate
healthcare and thus likely to exacerbate existing financial
hardship and economic instability.
The authors are currently part of a research group
that aims to study genetic biomarkers in the Pakistani
population. 
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